Introduction: Almost half of the cystic renal lesions are still overdiagnosed and overtreated. New clinical and radiological parameters are needed to distinguish the malignant Bosniak 3 lesions from the benign ones. We aimed to evaluate the clinical and radiological parameters that may be related to malignancy risk for Bosniak category 3 renal cysts. Materials and Methods: Patients who underwent surgical resection of a histopathologically confirmed Bosniak 3 renal cyst between March 2007 and September 2019 were evaluated. Two experienced uro-radiologists have reevaluated the last preoperative computed tomography and/or MRI images of the patients and reclassified the lesions according to the Bosniak classification. They also reported cystic features such as nodularity, septation, focal thickening, enhancement, and calcification. Clinical, pathological, and oncological outcomes were recorded. Then patients were divided into 2 groups as Group 1 (benign pathology) and Group 2 (malignant pathology) according to final histopathological report. Results: A total of 79 patients were included in this study. Mean follow-up time was 47 ± 34 months. There were 30 patients in Group 1 and 49 patients in Group 2. Hypertension (p = 0.001) and smoking history (p = 0.008) were more common in malignant group. Among the radiological findings, lower tumor diameter (p = 0.024), presence of cyst wall enhancement (p = 0.025), presence of nodularity (p = 0.002), and presence of focal thickening (p = 0.031) were found to be statistically significant for malignancy. Most of the tumors were at pathological T1 stage and Fuhrmann Grade 1–2. Only nodularity was found to be independent predictive factor for malignancy in multivariate analysis. Conclusion: Clinical factors including hypertension and smoking, radiological factors including lower lesion size, cyst wall enhancement, nodularity, and focal thickening were predictors for malignancy of Bosniak 3 cysts.

1.
Ljungberg
B
,
Albiges
L
,
Abu-Ghanem
Y
,
Bensalah
K
,
Dabestani
S
,
Fernández-Pello
S
, et al.
European association of urology guidelines on renal cell carcinoma: the 2019 update
.
Eur Urol
.
2019 May
;
75
(
5
):
799
810
. .
2.
Schoots
IG
,
Zaccai
K
,
Hunink
MG
,
Verhagen
PCMS
.
Bosniak classification for cmplex renal cyts reevaluated: a systematic review
.
J Urol
.
2017
;
198
:
12
21
.
3.
Kashan
M
,
Ghanaat
M
,
Hötker
AM
,
Duzgol
C
,
Sanchez
A
,
DiNatale
RG
, et al.
Cystic renal cell carcinoma: a report on outcomes of surgery and active surveillance in patients retrospectively identified on pretreatment imaging
.
J Urol
.
2018 Aug
;
200
(
2
):
275
82
. .
4.
Shaish
H
,
Ahmed
F
,
Schreiber
J
,
Hindman
NM
.
Active surveillance of small (<4 cm) Bosniak category 2F, 3, and 4 renal lesions: what happens on imaging follow-up?
AJR Am J Roentgenol
.
2019
;
212
(
6
):
1215
22
.
5.
Pruthi
DK
,
Liu
Q
,
Kirkpatrick
IDC
,
Gelfond
J
,
Drachenberg
DE
.
Long-term surveillance of complex cystic renal masses and heterogeneity of bosniak 3 lesions
.
J Urol
.
2018
;
200
(
6
):
1192
9
. .
6.
Israel
GM
,
Bosniak
MA
.
An update of the Bosniak renal cyst classification system
.
Urology
.
2005
;
66
(
3
):
484
. .
7.
Bosniak
MA
.
The current radiological approach to renal cysts
.
Radiology
.
1986
;
158
(
1
):
1
10
. .
8.
Silverman
SG
,
Pedrosa
I
,
Ellis
JH
,
Hindman
NM
,
Schieda
N
,
Smith
AD
, et al.
Bosniak classification of cystic renal masses, version 2019: an update proposal and needs assessment
.
Radiology
.
2019
;
292
(
2
):
475
88
. .
9.
Sefik
E
,
Bozkurt
IH
,
Adibelli
ZH
,
Aydin
ME
,
Celik
S
,
Oguzdogan
GY
, et al.
The histopathologic correlation of Bosniak 3 cyst subclassification
.
Urology
.
2019 July
;
129
:
126
31
. .
10.
Weibl
P
,
Hora
M
,
Kollarik
B
,
Shariat
SF
,
Klatte
T
.
Management, pathology and outcomes of Bosniak category IIF and III cystic renal lesions
.
World J Urol
.
2015
;
33
(
3
):
295
. .
11.
McLaughlin
JK
,
Lipworth
L
,
Tarone
RE
.
Epidemiologic aspects of renal cell carcinoma
.
Semin Oncol
.
2006 Oct
;
33
(
5
):
527
33
. .
12.
Reese
AC
,
Johnson
PT
,
Gorin
MA
,
Pierorazio
PM
,
Allaf
ME
,
Fishman
EK
, et al.
Pathological characteristics and radiographic correlates of complex renal cysts
.
Urol Oncol
.
2014 Oct
;
32
(
7
):
1010
6
. .
13.
Benjaminov
O
,
Atri
M
,
O'Malley
M
,
Lobo
K
,
Tomlinson
G
.
Enhancing component on CT to predict malignancy in cystic renal masses and interobserver agreement of different CT features
.
AJR Am J Roentgenol
.
2006
;
186
(
3
):
665
72
. .
14.
Song
C
,
Min
GE
,
Song
K
,
Kim
JK
,
Hong
B
,
Kim
CS
, et al.
Differential diagnosis of complex cystic renal mass using multiphase computerized tomography
.
J Urol
.
2009 Jun
;
181
(
6
):
2446
50
. .
15.
Erkkilä
K
,
Tornberg
SV
,
Järvinen
P
,
Järvinen
R
,
Kilpeläinen
TP
,
Visapää
H
, et al.
Evolving clinical picture of renal cell carcinoma: a population-based study from Helsinki
.
Urol Int
.
2019
;
102
(
4
):
390
8
. .
16.
Lam
CJ
,
Kapoor
A
.
The true malignancy risk of Bosniak III cystic renal lesions: active surveillance or surgical resection?
Can Urol Assoc J
.
2018
;
12
(
6
):
E276
80
. .
17.
Smith
AD
,
Carson
JD
,
Sirous
R
,
Sanyal
R
,
Remer
EM
,
Allen
BC
, et al.
Active surveillance versus nephron-sparing surgery for a Bosniak IIF or III renal cyst: a cost-effectiveness analysis
.
AJR Am J Roentgenol
.
2019 Apr
;
212
(
4
):
830
8
. .
18.
Yong
C
,
Stewart
GD
,
Frezza
C
.
Oncometabolites in renal cancer
.
Nat Rev Nephrol
.
2020 Mar
;
16
(
3
):
156
72
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.